The FDA clearance is a critical regulatory milestone for Quoin Pharmaceuticals, allowing it to expand its clinical trials to include a broader demographic. This development is perceived positively by the market, as evidenced by the substantial increase in trading volume and stock price. The inclusion of teens in the trials could potentially accelerate the drug's development and approval process, enhancing Quoin's market position and future revenue prospects.